Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10136052 | 0.94 | NPFFR1 (0.39) | L3MBTL1ALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL10046524 | 0.94 | NPFFR1 (0.39) | L3MBTL1ALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL2734924 | 0.87 | APLNR (0.36) | L3MBTL1ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3122796 | 0.87 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL26225129 | 0.86 | PCSK9 (0.38) | L3MBTL1ALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL18913815 | 0.85 | SMN1; SMN2 (0.35) | ALDH1A1KMT2ATSHRHPGDHSD17B10 | |
| SCHEMBL27324540 | 0.85 | MGLL (0.30) | — | |
| SCHEMBL5373649 | 0.84 | TDP1 (0.45) | L3MBTL1ALDH1A1KMT2AMEN1GAA | |
| SCHEMBL3402806 | 0.84 | TDP1 (0.47) | ALDH1A1KMT2AMEN1GAATDP1 | |
| SCHEMBL18946813 | 0.84 | MAPT (0.36) | L3MBTL1ALDH1A1KMT2ATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111732628-B | Synthetic method of GHK tripeptide | 中国计量大学 | 2022-04-05 | — | — | CN | claimed |
| EP-0326364-B1 | Renin inhibitory oligopeptides, their preparation and use | SANKYO CO (JP) | 1994-06-22 | — | — | EP | claimed |
| JP-57032298-A | — | — | None | — | — | JP | disclosed |
| JP-54061128-A | — | — | None | — | — | JP | disclosed |
| EP-4748843-A2 | ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104409-A1 | MULTIMERIC MANGANESE CONTRAST AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2026-05-21 | — | — | WO | disclosed |
| CN-122055172-A | Chimeric radiopharmaceuticals targeting the proton-sensitive receptor GPR4 | 安菲利克斯股份公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4741400-A1 | MULTIMERIC MANGANESE CONTRAST AGENTS | Bayer Aktiengesellschaft (DE) | 2026-05-13 | — | — | EP | disclosed |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2026-04-28 | — | — | US | disclosed |
| EP-4698170-A1 | GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS | Eberhard-Karls-Universität Tübingen (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-4476229-A | QUANTITATIVE ANALYSIS OF LIGANDS IN BIOLOGICAL FLUIDS | ABBOTT LABORATORIES (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0108399-A2 | Substituted carboxyfluoresceins | ABBOTT LABORATORIES (US) | 1984-05-16 | — | — | EP | disclosed |
| EP-0108563-A1 | 3-Demethoxyistamycin B and its 2\"-N-formimidoyl derivative | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1984-05-16 | — | — | EP | disclosed |
| EP-0083923-A2 | Aminoacyl-containing dipeptide derivatives useful as antihypertensives | MERCK & CO. INC. (US) | 1983-07-20 | — | — | EP | disclosed |
| EP-0059966-A1 | Substituted thiazolidine carboxylic acid analogs and derivatives as antihypertensives | MERCK & CO. INC. (US) | 1982-09-15 | — | — | EP | disclosed |
| JP-S5732298-A | FORMIMIDOYL ISTAMYCIN A AND ITS PREPARATION | MICROBIAL CHEM RES FOUND | 1982-02-20 | — | — | JP | disclosed |
| US-4273704-A | N-Adamantane-substituted tetrapeptide amides | G. D. SEARLE & CO. (US) | 1981-06-16 | — | — | US | disclosed |
| JP-S5461128-A | PEPTIDE DERIVATIVE | AJINOMOTO CO INC | 1979-05-17 | — | — | JP | disclosed |
| JP-S05461128-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, ARGLU1 | L3MBTL1 689/4885ALDH1A1 1523/4885KMT2A 557/4885 |
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | CCR6, OGFRL1, IL6ST | L3MBTL1 1292/4885ALDH1A1 4268/4885KMT2A 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.